Wuhan Hiteck Biological Pharma Co.,Ltd reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported sales was CNY 438.43 million compared to CNY 546.64 million a year ago. Revenue was CNY 438.43 million compared to CNY 546.64 million a year ago.

Net loss was CNY 26.44 million compared to net income of CNY 18.82 million a year ago. Basic loss per share from continuing operations was CNY 0.21 compared to basic earnings per share from continuing operations of CNY 0.15 a year ago. Diluted loss per share from continuing operations was CNY 0.21 compared to diluted earnings per share from continuing operations of CNY 0.15 a year ago.